Previous 10 |
SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the pr...
Cytori Therapeutics (NASDAQ: CYTX ) has filed a prospectus for an unspecified public offering of Class A and Class B Units. More news on: Cytori Therapeutics Inc, Healthcare stocks news, Stocks on the move, Read more ...
Thinly traded nano cap Cytori Therapeutics ( CYTX +12.1% ) is up on an 11x surge in volume in reaction to the publication in the journal Gastroenterology of results from an investigator-initiated pilot study in France assessing Cytori Cell Therapy for the treatment of perianal fistula ...
SAN DIEGO, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announces the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of refractory perianal fistula in patients with Crohnȁ...
News, Short Squeeze, Breakout and More Instantly...
Cytori Therapeutics Inc. Company Name:
CYTX Stock Symbol:
NASDAQ Market:
Cytori Therapeutics Inc. Website:
AUSTIN, Texas, July 16, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq: CYTX) (the “company”) announced yesterday a new direction and identity. Since the beginning of 2019, the company has successfully evaluated and transformed its pipeline to place a stronger e...
SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) “the Company” will provide a live webcast to discuss its new company direction following two recent asset sales and highlight key anticipated milestones on July 15, 2019 at 4:30 PM Eastern Ti...
AUSTIN, Texas, July 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an update on the development of its proprietary drug, ATI-1123, based on recently obtained feedback from the United States Food and Drug Administration (FDA). ATI-1123 is a substantially...